{"title":"Mechanisms of chemotherapy-induced oocyte death through activation of TAp63α.","authors":"Niklas Gutfreund, Marcel Tuppi, Birgit Schäfer, Francesca Gioia Klinger, Anja Kirchhof, Antonia Hofmann, Ivan Dikic, Volker Dötsch","doi":"10.1530/REP-24-0225","DOIUrl":null,"url":null,"abstract":"<p><strong>In brief: </strong>Induction of DNA double-strand breaks results in oocyte death caused by the activation of TAp63α. This study investigates which chemotherapeutic drugs activate p63 and which cause oocyte death without p63 activation.</p><p><strong>Abstract: </strong>Primary ovarian insufficiency is a severe side effect of classical chemotherapy and radiotherapy in treatment of female cancer patients of reproductive age. The p53-homolog TAp63α emerged as the key protein regulating apoptosis following DNA damage in oocytes of primordial follicles. In this study, we monitored the toxicity of widely used chemotherapeutic agents on oocytes of primordial follicles utilizing a GFP-c-kit transgenic mouse model, the involvement of active TAp63α and the mechanism of action leading to its activation. Our studies show that alkylating agents and topoisomerase II poisons are potent activators of TAp63α by directly inducing DNA damage. Oxidative stress and DNA intercalation were not sufficient to trigger TAp63α activation despite showing a strong general toxicity. These results are in agreement with several previous investigations that have demonstrated that DNA double-strand breaks are the most effective way to initiate apoptosis in oocytes of primordial follicles. The widely used catalytic topoisomerase II inhibitor ICRF-187 was able to prevent activation of TAp63α by the topoisomerase II poison doxorubicin but did not prevent oocyte death, suggesting an alternative mechanism of cell death induction.</p>","PeriodicalId":21127,"journal":{"name":"Reproduction","volume":"169 5","pages":""},"PeriodicalIF":3.7000,"publicationDate":"2025-04-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Reproduction","FirstCategoryId":"99","ListUrlMain":"https://doi.org/10.1530/REP-24-0225","RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/5/1 0:00:00","PubModel":"Print","JCR":"Q1","JCRName":"DEVELOPMENTAL BIOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
In brief: Induction of DNA double-strand breaks results in oocyte death caused by the activation of TAp63α. This study investigates which chemotherapeutic drugs activate p63 and which cause oocyte death without p63 activation.
Abstract: Primary ovarian insufficiency is a severe side effect of classical chemotherapy and radiotherapy in treatment of female cancer patients of reproductive age. The p53-homolog TAp63α emerged as the key protein regulating apoptosis following DNA damage in oocytes of primordial follicles. In this study, we monitored the toxicity of widely used chemotherapeutic agents on oocytes of primordial follicles utilizing a GFP-c-kit transgenic mouse model, the involvement of active TAp63α and the mechanism of action leading to its activation. Our studies show that alkylating agents and topoisomerase II poisons are potent activators of TAp63α by directly inducing DNA damage. Oxidative stress and DNA intercalation were not sufficient to trigger TAp63α activation despite showing a strong general toxicity. These results are in agreement with several previous investigations that have demonstrated that DNA double-strand breaks are the most effective way to initiate apoptosis in oocytes of primordial follicles. The widely used catalytic topoisomerase II inhibitor ICRF-187 was able to prevent activation of TAp63α by the topoisomerase II poison doxorubicin but did not prevent oocyte death, suggesting an alternative mechanism of cell death induction.
期刊介绍:
Reproduction is the official journal of the Society of Reproduction and Fertility (SRF). It was formed in 2001 when the Society merged its two journals, the Journal of Reproduction and Fertility and Reviews of Reproduction.
Reproduction publishes original research articles and topical reviews on the subject of reproductive and developmental biology, and reproductive medicine. The journal will consider publication of high-quality meta-analyses; these should be submitted to the research papers category. The journal considers studies in humans and all animal species, and will publish clinical studies if they advance our understanding of the underlying causes and/or mechanisms of disease.
Scientific excellence and broad interest to our readership are the most important criteria during the peer review process. The journal publishes articles that make a clear advance in the field, whether of mechanistic, descriptive or technical focus. Articles that substantiate new or controversial reports are welcomed if they are noteworthy and advance the field. Topics include, but are not limited to, reproductive immunology, reproductive toxicology, stem cells, environmental effects on reproductive potential and health (eg obesity), extracellular vesicles, fertility preservation and epigenetic effects on reproductive and developmental processes.